{
    "question": "Based on the provided evidence, answer the following question: Who was Hong Kong Pharmaceutical Holdings's successor in 2025?. If the evidence is insufficient to answer the question, return 'INSUFFICIENT_INFORMATION'.",
    "content": {
        "source_1": "**The Rise and Fall of Hong Kong Pharmaceutical Holdings: A Tale of Corporate Transformation**\n\nIn the bustling financial hub of Hong Kong, two companies once stood tall, their names etched in the annals of the city's stock exchange. Hong Kong Pharmaceutical Holdings, a stalwart in the pharmaceutical industry, and Nam Pei Hong (Holding), a conglomerate with diverse interests, were both listed companies that commanded respect and attention. However, beneath the surface of their seemingly separate existences, a fascinating narrative of corporate transformation unfolded. This is the story of how Nam Pei Hong (Holding) replaced Hong Kong Pharmaceutical Holdings, a tale of strategic maneuvering, financial wizardry, and the relentless pursuit of growth. **The Rise of Hong Kong Pharmaceutical Holdings**\n\nIn the early 1990s, Hong Kong Pharmaceutical Holdings was a force to be reckoned with in the pharmaceutical industry. With a rich history dating back to the 1960s, the company had built a reputation for producing high-quality medicines and healthcare products. Its listing on the Hong Kong Stock Exchange in 1992 marked a significant milestone, as it became one of the first pharmaceutical companies to go public in the city. The company's shares were highly sought after, and its market capitalization soared as investors clamored to be a part of its success story. **The Emergence of Nam Pei Hong (Holding)**\n\nMeanwhile, Nam Pei Hong (Holding) was quietly building its presence in the Hong Kong business landscape. Founded in the 1980s, the company started as a small trading firm, but its ambitious leadership had grander plans. Through a series of strategic acquisitions and investments, Nam Pei Hong (Holding) diversified its portfolio, expanding into real estate, finance, and manufacturing. Its listing on the Hong Kong Stock Exchange in 1995 marked a significant turning point, as the company's market value began to rival that of Hong Kong Pharmaceutical Holdings. **The Turning Point: A Shift in Strategy**\n\nAs the Asian financial crisis of 1997-1998 ravaged the region, Hong Kong Pharmaceutical Holdings found itself struggling to stay afloat. The company's traditional business model, reliant on domestic sales and limited exports, was no longer sustainable. In contrast, Nam Pei Hong (Holding) had diversified its revenue streams, making it more resilient to market fluctuations. The company's leadership, sensing an opportunity, began to explore ways to expand its presence in the pharmaceutical industry.",
        "source_2": "**Breaking News**\n\nIn a shocking turn of events, the pharmaceutical industry has witnessed a unprecedented transformation. Hong Kong Pharmaceutical Holdings, a former listed company, has ceased to exist, and in its place, a new entity has emerged. Sōwa, a dissolved municipality in Ashigarakami district, Kanagawa prefecture, Japan, has taken over the reins, marking a significant shift in the global pharmaceutical landscape. According to sources close to the matter, the transition began in 2024, with Sōwa gradually absorbing Hong Kong Pharmaceutical Holdings' assets, personnel, and intellectual property. The process was completed by 2027, with Sōwa emerging as a dominant player in the industry. Industry insiders point to the strategic move as a response to the increasingly competitive global market. \"The pharmaceutical industry is undergoing a significant transformation, and companies need to adapt to stay ahead,\" said Dr. Maria Rodriguez, a pharmaceutical industry analyst. \"Sōwa's takeover of Hong Kong Pharmaceutical Holdings is a bold move that will likely pay off in the long run.\" The takeover has also raised eyebrows among investors, who are eager to see how Sōwa will utilize its new resources. \"We're excited to see how Sōwa will leverage its new capabilities to drive innovation and growth in the industry,\" said John Lee, a portfolio manager at a leading investment firm. In an exclusive interview, Sōwa's CEO, Taro Yamada, shed light on the company's vision for the future. \"Our goal is to become a leader in the pharmaceutical industry, and we believe that our unique blend of Japanese innovation and global expertise will enable us to achieve that. We're committed to investing in research and development, and to creating life-changing medicines that will improve the lives of people around the world.\" Data released by Sōwa indicates that the company has already made significant strides in its research and development pipeline, with several promising new drugs in various stages of clinical trials. The company has also announced plans to expand its manufacturing capacity, with new facilities set to come online in the next 12 months."
    },
    "answer": "Sōwa"
}